Taysha Gene Therapies (TSHA) - EV/EBITDA Multiple

Taysha Gene Therapies (TSHA) production capacities are functioning stably due to precise drug dosing. The company's EV/EBITDA fluctuations reflect the current market trend, where 0.00 serves as the final level mark. Growth is based on the priority rollout of drugs for monogenic pathologies. Niche protection is ensured by strict patenting, while success depends on orphan status and clinical trial results.
TSHA (Taysha Gene Therapies Inc): analytical breakdowns and indicator data

This ratio compares the total enterprise value, including net debt, to its operating profit before depreciation and amortization, determining the market value of one ruble of profit and the company's resilience to external shocks. For Taysha Gene Therapies (TSHA), which is developing a CNS gene therapy platform, the company's current EV/EBITDA multiple serves as an indicator of the capitalization of its technological potential, allowing for an assessment of the fundamental value of its mutation correction method development.